Compare BridgeBio Pharma Inc (BBIO) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Jumia Technologies AG - ADR — how do they compare? BridgeBio Pharma Inc trades at $83.21 (market cap $16.46B), while Jumia Technologies AG - ADR trades at $6.9 (market cap $848.39M). The key difference: BridgeBio Pharma Inc is far larger — about 19.4× Jumia Technologies AG - ADR's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| BBIO | JMIA | |
|---|---|---|
Market Cap | $16.46B | $848.39M |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $14.60 |
52-Week Low | $44.81 | $4.45 |
Enterprise Value | $18.02B | $795.49M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
JMIA trades at $6.71, down 4.28% today, amid bearish technical signals despite analyst optimism. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses, targeting 2027 profitability. Recent Q1 2026 results beat GMV guidance with 39% revenue growth, though EPS missed expectations. Cash flow turned positive in 2024-2025 after years of negative net flows.
Outlook remains speculative with high execution risk despite 71% analyst buy ratings. The path to profitability depends on successful African market expansion and cost management. Key risks include persistent losses, competitive pressures, and macroeconomic challenges in operating markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
